
An exoplanet called K2-18b is highlighting the complexities of finding life beyond Earth
A tiny sign revealed in April seemed like it might change the universe as we know it.
Astronomers had detected just a hint, a glimmer of two molecules swirling in the atmosphere of a distant planet called K2-18b — molecules that on Earth are produced only by living things. It was a tantalizing prospect: the most promising evidence yet of an extraterrestrial biosignature, or traces of life linked to biological activity.
But only weeks later, new findings suggest the search must continue.
'It was exciting, but it immediately raised several red flags because that claim of a potential biosignature would be historic, but also the significance or the strength of the statistical evidence seemed to be too high for the data,' said Dr. Luis Welbanks, a postdoctoral research scholar at Arizona State University's School of Earth and Space Exploration.
While the molecules identified on K2-18b by the April study — dimethyl sulfide, or DMS, and dimethyl disulfide, or DMDS — are associated largely with microbial organisms on our planet, scientists point out that the compounds can also form without the presence of life. Now, three teams of astronomers not involved with the research, including Welbanks, have assessed the models and data used in the original biosignature discovery and got very different results, which they have submitted for peer review.
Meanwhile, the lead author of the April study, Nikku Madhusudhan, and his colleagues have conducted additional research that they say reinforces their previous finding about the planet. And it's likely that additional observations and research from multiple groups of scientists are on the horizon.
The succession of research papers revolving around K2-18b offers a glimpse of the scientific process unfolding in real time. It's a window into the complexities and nuances of how researchers search for evidence of life beyond Earth — and shows why the burden of proof is so high and difficult to reach.
Located 124 light-years from Earth, K2-18b is generally considered a worthy target to scour for signs of life. It is thought to be a Hycean world, a planet entirely covered in liquid water with a hydrogen-rich atmosphere, according to previous research led by Madhusudhan, a professor of astrophysics and exoplanetary science at the University of Cambridge's Institute of Astronomy. And as such, K2-18b has rapidly attracted attention as a potentially habitable place beyond our solar system.
Convinced of K2-18b's promise, Madhusudhan and his Cambridge colleagues used observations of the planet by the largest space telescope in operation, the James Webb Space Telescope, to study the planet further. But two scientists at the University of Chicago — Dr. Rafael Luque, a postdoctoral scholar in the university's department of astronomy and astrophysics, and Michael Zhang, a 51 Pegasi b / Burbidge postdoctoral fellow — spotted some problems with what they found.
After reviewing Madhusudhan and his team's April paper, which followed up on their 2023 research, Luque and Zhang noticed that the Webb data looked 'noisy,' Luque said.
Noise, caused by imperfections in the telescope and the rate at which different particles of light reach the telescope, is just one challenge astronomers face when they study distant exoplanets. Noise can distort observations and introduce uncertainties into the data, Zhang said.
Trying to detect specific gases in distant exoplanet atmospheres introduces even more uncertainty. The most noticeable features from a gas like dimethyl sulfide stem from a bond of hydrogen and carbon molecules — a connection that can stretch and bend and absorb light at different wavelengths, making it hard to definitively detect one kind of molecule, Zhang said.
'The problem is basically every organic molecule has a carbon-hydrogen bond,' Zhang said. 'There's hundreds of millions of those molecules, and so these features are not unique. If you have perfect data, you can probably distinguish between different molecules. But if you don't have perfect data, a lot of molecules, especially organic molecules, look very similar, especially in the near-infrared.'
Delving further into the paper, Luque and Zhang also noticed that the perceived temperature of the planet appeared to increase sharply from a range of about 250 Kelvin to 300 Kelvin (-9.67 F to 80.33 F or -23.15 C to 26.85 C) in research Madhusudhan published in 2023 to 422 Kelvin (299.93 F or 148.85 C) in the April study.
Such harsh temperatures could change the way astronomers think about the planet's potential habitability, Zhang said, especially because cooler temperatures persist in the top of the atmosphere — the area that Webb can detect — and the surface or ocean below would likely have even higher temperatures.
'This is just an inference only from the atmosphere, but it would certainly affect how we think about the planet in general,' Luque said.
Part of the issue, he said, is that the April analysis didn't include data collected from all three Webb instruments Madhusudhan's team used over the past few years. So Luque, Zhang and their colleagues conducted a study combining all the available data to see whether they could achieve the same results, or even find a higher amount of dimethyl sulfide. They found 'insufficient evidence' of both molecules in the planet's atmosphere.
Instead, Luque and Zhang's team spotted other molecules, like ethane, that could fit the same profile. But ethane does not signify life.
Arizona State's Welbanks and his colleagues, including Dr. Matt Nixon, a postdoctoral researcher in the department of astronomy at the University of Maryland College Park, also found what they consider a fundamental problem with the April paper on K2-18b.
The concern, Welbanks said, was with how Madhusudhan and his team created models to show which molecules might be in the planet's atmosphere.
'Each (molecule) is tested one at a time against the same minimal baseline, meaning every single model has an artificial advantage: It is the only explanation permitted,' Welbanks said.
When Welbanks and his team conducted their own analysis, they expanded the model from Madhusudhan's study.
'(Madhusudhan and his colleagues) didn't allow for any other chemical species that could potentially be producing these small signals or observations,' Nixon said. 'So the main thing we wanted to do was assess whether other chemical species could provide an adequate fit to the data.'
When the model was expanded, the evidence for dimethyl sulfide or dimethyl disulfide 'just disappears,' Welbanks said.
Madhusudhan believes the studies that have come out after his April paper are 'very encouraging' and 'enabling a healthy discussion on the interpretation of our data on K2-18b.'
He reviewed Luque and Zhang's work and agreed that their findings don't show a 'strong detection for DMS or DMDS.' When Madhusudhan's team published the paper in April, he said the observations reached the three-sigma level of significance, or a 0.3% probability that the detections occurred by chance.
For a scientific discovery that is highly unlikely to have occurred by chance, the observations must meet a five-sigma threshold, or below a 0.00006% probability that the observations occurred by chance. Meeting such a threshold will require many steps, Welbanks said, including repeated detections of the same molecule using multiple telescopes and ruling out potential nonbiological sources.
While such evidence could be found in our lifetime, it is less likely to be a eureka moment and more a slow build requiring a consensus among astronomers, physicists, biologists and chemists.
'We have never reached that level of evidence in any of our studies,' Madhusudhan wrote in an email. 'We have only found evidence at or below 3-sigma in our two previous studies (Madhusudhan et al. 2023 and 2025). We refer to this as moderate evidence or hints but not a strong detection. I agree with (Luque and Zhang's) claim which is consistent with our study and we have discussed the need for stronger evidence extensively in our study and communications.'
In response to the research conducted by Welbanks' team, Madhusudhan and his Cambridge colleagues have authored another manuscript expanding the search on K2-18b to include 650 types of molecules. They have submitted the new analysis for peer review.
'This is the largest search for chemical signatures in an exoplanet to date, using all the available data for K2-18b and searching through 650 molecules,' Madhusudhan said. 'We find that DMS continues to be a promising candidate molecule in this planet, though more observations are required for a firm detection as we have noted in our previous studies.'
Welbanks and Nixon were pleased that Madhusudhan and his colleagues addressed the concerns raised but feel that the new paper effectively walks back central claims made in the original April study, Welbanks said.
'The new paper tacitly concedes that the DMS/DMDS detection was not robust, yet still relies on the same flawed statistical framework and a selective reading of its own results,' Welbanks said in an email. 'While the tone is more cautious (sometimes), the methodology continues to obscure the true level of uncertainty. The statistical significance claimed in earlier work was the product of arbitrary modeling decisions that are not acknowledged.'
Luque said the Cambridge team's new paper is a step in the right direction because it explores other possible chemical biosignatures.
'But I think it fell short in the scope,' Luque said. 'I think it restricted itself too much into being a rebuttal to the (Welbanks) paper.'
Separately, however, the astronomers studying K2-18b agree that pushing forward on researching the exoplanet contributes to the scientific process.
'I think it's just a good, healthy scientific discourse to talk about what is going on with this planet,' Welbanks said. 'Regardless of what any single author group says right now, we don't have a silver bullet. But that is exactly why this is exciting, because we know that we're the closest we have ever been (to finding a biosignature), and I think we may get it within our lifetime, but right now, we're not there. That is not a failure. We're testing bold ideas.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
What the Trump-Musk Feud Means for SpaceX and NASA
The U.S. government relies on SpaceX to support NASA and other agencies, and the company has received more $20 billion in federal contracts for it. As Musk and Trump threaten to cut ties, here's what that would mean for the U.S.'s space ambitions.


Health Line
2 hours ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.


Screen Geek
2 hours ago
- Screen Geek
2025 Box Office Bomb Dominates HBO Max
Subscribers on HBO Max are flocking to one of 2025's box office bombs as the film unexpectedly tops the streaming service's charts. Of course, it's not surprising that this 2025 effort is doing so well on HBO Max following its theatrical release, especially when one considers that it comes from an acclaimed director. As noted via FlixPatrol, at the time of this writing, this film is the #2 title on the streaming platform. It's quite a feat for a movie that struggled at the box office, having earned just barely more than its budget at the box office, grossing $132 million against a $118 million production cost. Impressively, the title stars Robert Pattinson as the lead, with Naomi Ackie, Steven Yeun, Toni Collette, and Mark Ruffalo. Bong Joon Ho both wrote and directed the film which was based on a novel by Edward Ashton. It seems as though the talent from everyone involved has given this title legs beyond its theatrical release. This 2025 film now streaming on HBO Max is none other than Mickey 17 , a sci-fi film set in the year 2054. It revolves around Pattinson's character who joins a space colony. His official title is that of an 'Expendable,' which is an individual that happens to be cloned upon death. While a majority of their memories are retained, they quickly become diluted with each additional copy. It's an interesting endeavor from Bong Joon Ho, and one that probably should have fared better at the box office. Fortunately, it looks like it has been earning viewers with its newfound availability on HBO Max and home video. Stay tuned to ScreenGeek for any additional updates regarding the latest trending titles on HBO Max as we have them. For now, subscribers are able to see Mickey 17 for themselves, and see whether or not the title was deserving of a better box office performance. Especially now that it appears to be doing quite well on streaming.